ToxiPharm LLC

ToxSignal

Clinical Toxicology Intelligence

Issue

#01

May 2026

Now Detected in 37% of Fentanyl Samples — And It Isn't Xylazine

Medetomidine — a veterinary alpha-2 agonist used as an animal sedative — has gone from appearing in 4% of fentanyl samples in May 2024 to 37% as of October 2025. It is 100 to 200 times more potent than xylazine, and it produces a distinct withdrawal syndrome that sets it apart: rapid-onset tachycardia, severe hypertension, vomiting, and altered mental status beginning within hours of last use, peaking at 18 to 36 hours. New York City issued a clinical health advisory in early 2026 following a cluster of cases. Naloxone does not reverse medetomidine's effects; clinical management requires dexmedetomidine infusion, antiemetics, and toxicology consultation.

Sources: NPR, Apr 14  |  MMWR / CDC Surveillance Data

DOT Makes It Official: Zero Certified Labs, Directly Observed Urine as Workaround — Effective June 10

DOT authorized oral fluid drug testing for federal workplace programs in May 2023. Three years later, as of the May 11 Federal Register notice, zero HHS-certified laboratories exist to conduct that testing. The interim rule (effective June 10, 2026) formalizes the workaround: when an employer's program specifies oral fluid and no certified lab is available, a directly observed urine collection must be substituted. If you have clients operating DOT-covered drug testing programs, they need to know about this before June 10.

Federal Register, May 11, 2026  |  DOT / PHMSA  |  Effective June 10, 2026

White House Releases Treatment-First Drug Strategy — Same Week as Reports of $245M in SAMHSA Cuts

The 2026 National Drug Control Strategy, released May 5, calls for making treatment more accessible than drugs and reducing overdose deaths. Within 24 hours, reporting by KFF Health News and Healthbeat confirmed the Administration's budget reconciliation bill includes Medicaid work requirements projected to strip coverage from approximately 1.6 million people with substance use disorders, and at least $245 million in SAMHSA grant funding has already been cut since January 2026. Medicaid is the dominant payer for OTP patients. The gap between stated strategy and operational funding is the story to watch through the rest of 2026.

KFF Health News  |  Healthbeat, May 6  |  White House ONDCP, May 5, 2026

JAMA NETWORK OPEN

"Consensus Best Practices for Hospital-Initiated Medications for Opioid Use Disorder"

A 42-expert Delphi panel published the first comprehensive national consensus on hospital-initiated MOUD, covering rapid methadone induction, high-dose and low-dose buprenorphine initiation, opioid withdrawal adjunct management, and long-acting injectable buprenorphine. For clinicians managing the hospital-to-OTP transition, this is the new standard-of-care reference. For consulting clients, non-conformance with published expert consensus carries real liability and accreditation implications. The methadone and buprenorphine initiation tables alone are worth pulling out for protocol review.

Delphi Expert Panel, 2026  |  Read it →

JAMA

"Extended-Release vs. Sublingual Buprenorphine Initiated in the Emergency Department: A Randomized Clinical Trial"

This 29-site RCT compared 7-day injectable ER-buprenorphine against sublingual buprenorphine for ED-initiated OUD treatment. The result: 30-day engagement was essentially equivalent (40.5% vs. 38.5%, not statistically different), and precipitated withdrawal was rare in both groups (under 1%). The practical takeaway is that ER-injectable buprenorphine is a clinically viable bridge for patients who cannot yet access daily dosing — which has direct implications for OTP intake planning when patients arrive post-ED visit.

Multicenter RCT, JAMA 2026 (PMID 41670966)  |  Read it →